早期间质性肺病的胶原蛋白靶向 PET 成像
The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.
研究概览
详细说明
[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.
The goals of this study are:
- To determine whether collagen deposition as assessed by [68Ga]CBP8-PET MRI can detect increased collagen deposition in early interstitial lung disease and
- if the degree of [68Ga]CBP8 uptake predicts subsequent disease progression.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Sydney B Montesi, MD
- 电话号码:617-724-4030
- 邮箱:sbmontesi@partners.org
研究联系人备份
- 姓名:Abimbola Akinniyi
- 电话号码:781-513-0207
- 邮箱:aakinniyi@mgb.org
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital
-
首席研究员:
- Sydney Montesi, MD
-
接触:
- Abimbola Akinniyi
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)
- Age greater than 40 years
- Have the ability to give written informed consent
- First degree relative of a family member with pulmonary fibrosis
- No known history of interstitial lung disease
- No tobacco use within the prior 6 months.
Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)
- Age greater than 40 years
- Have the ability to give written informed consent
- ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern)
- No tobacco use within the prior 6 months.
Exclusion criteria:
- Electrical implants such as cardiac pacemaker or perfusion pump
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
- Historical eGFR of less than 30 mL/min/1.73 m2
- Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate)
- Claustrophobic reactions
- Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)
- Unable to lie comfortably on a bed inside the MR-PET
- BMI > 33 (limit of the PET-MRI table)
- Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures)
- Pneumonia or other acute respiratory illness within 6 weeks of study entry
- Parenchymal lung disease except for ILD/ILAs or emphysema
- Acute exacerbation of ILD within the prior 6 months
- VATS within the prior 6 months
- Prior radiation therapy to the thorax
- Known allergy to gadolinium.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)
Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive [68Ga]CBP8 and undergo PET-MRI. |
An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI. Dotarem will be administered during MRI portion of study.
其他名称:
|
|
实验性的:First degree relatives of a family member with pulmonary fibrosis
First degree relatives of a family member with pulmonary fibrosis will receive [68Ga]CBP8 and undergo PET-MRI. |
An injection of up to 350 MBq of [68Ga]CBP8 will be administered intravenously followed by PET-MRI. Dotarem will be administered during MRI portion of study.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Degree of uptake of [68Ga]CBP8
大体时间:24 months
|
The degree of uptake of [68Ga]CBP8 in the lungs will be compared between groups and associations with disease severity and progression will be determined. |
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of MRI contrast clearance, Kwashout, in the lungs
大体时间:24 months
|
Kwashout rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
|
Rate of MRI contrast arrival, Kwashin, in the lungs
大体时间:24 months
|
Kwashin rates will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
|
Peak enhancement of MRI contrast in the lungs
大体时间:24 months
|
Peak enhancement will be compared between groups and associations with disease severity, progression, and degree of uptake of [68Ga]CBP8 will be determined. |
24 months
|
合作者和调查者
出版物和有用的链接
一般刊物
- Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available.
- Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.